Morgan P F, Stone T W
J Neurochem. 1982 Nov;39(5):1446-51. doi: 10.1111/j.1471-4159.1982.tb12590.x.
Specific binding of [3H]diazepam at a free concentration of 2 nM was found to be maximally potentiated by 117% in Tris-HCl buffer and 160% in Tris-citrate buffer by ethylenediamine (EDA), but only at relatively high concentrations of EDA (ED50 = 5 X 10(-5) M), although this potentiation was susceptible to a low dose (6 microM) of bicuculline. Dose-response curves show that EDA differs from GABA with respect to both potency and efficacy. In additivity experiments no evidence was found that EDA could act as a partial agonist at GABA receptors, and it was concluded that EDA and GABA apparently do not potentiate [3H]diazepam binding by acting on the same receptor. Scatchard analysis lends support to this hypothesis, indicating that the potentiation of [3H]diazepam binding by 3.16 X 10(-3) M EDA is due to an increase in receptor number (from 930 to 1170 fmol/mg protein) and not receptor affinity (remaining constant about 20 nM). Subsequent studies showed the potentiation to be reversible. It is concluded that EDA can act on the GABA-benzodiazepine receptor ionophore complex but that this is probably not a direct action on the GABA receptor. It is suggested that EDA can be used to differentiate GABA receptors linked to benzodiazepine receptors from those not so linked.
在2 nM的游离浓度下,发现[3H]地西泮的特异性结合在Tris-HCl缓冲液中被乙二胺(EDA)最大程度增强了117%,在Tris-柠檬酸盐缓冲液中增强了160%,但仅在相对高浓度的EDA(ED50 = 5×10(-5) M)时才会如此,尽管这种增强作用对低剂量(6 microM)的荷包牡丹碱敏感。剂量反应曲线表明,EDA在效力和效能方面均与GABA不同。在加和性实验中,未发现EDA可作为GABA受体的部分激动剂的证据,得出的结论是,EDA和GABA显然不是通过作用于同一受体来增强[3H]地西泮的结合。Scatchard分析支持了这一假设,表明3.16×10(-3) M EDA对[3H]地西泮结合的增强作用是由于受体数量增加(从930增加到1170 fmol/mg蛋白质),而不是受体亲和力增加(保持在约20 nM不变)。随后的研究表明这种增强作用是可逆的。得出的结论是,EDA可作用于GABA-苯二氮䓬受体离子通道复合物,但这可能不是对GABA受体的直接作用。有人提出,EDA可用于区分与苯二氮䓬受体相连的GABA受体和未相连的GABA受体。